Hepatitis B Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2500
Buy Report View Sample

Published: September 30, 2022 Report Code: GDGMDHC22350IDB-ST

Select Item

Hepatitis B Pipeline Products Market Overview

The Hepatitis B virus can cause an acute illness with symptoms that last several weeks, including yellowing of the skin and eyes (jaundice), dark urine, extreme fatigue, nausea, vomiting, and abdominal pain.

The Hepatitis B pipeline market research report provides comprehensive information on the therapeutics under development for Hepatitis B, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hepatitis B and features dormant and discontinued projects.

Key Targets Hepatitis B Virus Surface Antigen, Capsid Protein, Interferon Alpha/Beta Receptor 1, Interferon Alpha/Beta Receptor 2, Reverse Transcriptase, Sodium/Bile Acid Cotransporter, Hepatitis B Virus Core Antigen, Hepatitis B Virus DNA Polymerase, Programmed Cell Death 1 Ligand 1, Toll Like Receptor 7, and Others
Key Mechanisms of Action Hepatitis B Virus Surface Antigen Inhibitor, Capsid Protein Inhibitor, Interferon Alpha/Beta Receptor 1 Agonist, Interferon Alpha/Beta Receptor 2 Agonist, Reverse Transcriptase Inhibitor, Sodium/Bile Acid Cotransporter Inhibitor, Programmed Cell Death 1 Ligand 1 Inhibitor, Toll Like Receptor 7 Agonist, Toll Like Receptor 8 Agonist, DNA Polymerase Inhibitor, and Others
Key Routes of Administration Oral, Subcutaneous, Intramuscular, Intravenous, Parenteral, Intradermal, Inhalational, Intralesional, Intrathecal, Intrauterine, and Others
Key Molecule Type Small Molecule, Subunit Vaccine, Antisense RNAi Oligonucleotide, Monoclonal Antibody, Recombinant Vector Vaccine, Vaccine, Gene Therapy, DNA Vaccine, Recombinant Protein, Cell Therapy, and Others
Leading Players Aligos Therapeutics Inc, Tekmira Pharmaceuticals Corporation, Assembly Biosciences Inc, Johnson & Johnson, Beijing Kawin Technology Share-Holding Co Ltd, Vir Biotechnology Inc, Antios Therapeutics Inc, Ascletis Pharma Inc, F. Hoffmann-La Roche Ltd, and Shanghai Zhimeng Biopharma Inc

Hepatitis B Pipeline Products Market Segmentation by Targets

The key targets in the Hepatitis B pipeline products market are Hepatitis B Virus Surface Antigen, Capsid Protein, Interferon Alpha/Beta Receptor 1, Interferon Alpha/Beta Receptor 2, Reverse Transcriptase, Sodium/Bile Acid Cotransporter, Hepatitis B Virus Core Antigen, Hepatitis B Virus DNA Polymerase, Programmed Cell Death 1 Ligand 1, Toll Like Receptor 7, and others.

Hepatitis B Pipeline Products Market Analysis by Targets

Hepatitis B Pipeline Products Market Analysis by Targets

For more target insights into the Hepatitis B pipeline products market, download a free report sample

Hepatitis B Pipeline Products Market Segmentation by Mechanisms of Action

The key mechanisms of action in the Hepatitis B pipeline products market are Hepatitis B Virus Surface Antigen Inhibitor, Capsid Protein Inhibitor, Interferon Alpha/Beta Receptor 1 Agonist, Interferon Alpha/Beta Receptor 2 Agonist, Reverse Transcriptase Inhibitor, Sodium/Bile Acid Cotransporter Inhibitor, Programmed Cell Death 1 Ligand 1 Inhibitor, Toll Like Receptor 7 Agonist, Toll Like Receptor 8 Agonist, DNA Polymerase Inhibitor, and others.

Hepatitis B Pipeline Products Market Analysis by Mechanisms of Action

Hepatitis B Pipeline Products Market Analysis by Mechanisms of Action

For more mechanisms of action insights into the Hepatitis B pipeline products market, download a free report sample

Hepatitis B Pipeline Products Market Segmentation by Routes of Administration

The key routes of administration in the Hepatitis B pipeline products market are oral, subcutaneous, intramuscular, intravenous, parenteral, intradermal, inhalational, intralesional, intrathecal, intrauterine, and others.

Hepatitis B Pipeline Products Market Analysis by Routes of Administration

Hepatitis B Pipeline Products Market Analysis by Routes of Administration

For more routes of administration insights into the Hepatitis B pipeline products market, download a free report sample

Hepatitis B Pipeline Products Market Segmentation by Molecule Types

The key molecule types in the Hepatitis B pipeline products market are small molecule, subunit vaccine, antisense RNAi oligonucleotide, monoclonal antibody, recombinant vector vaccine, vaccine, gene therapy, DNA vaccine, recombinant protein, cell therapy, and others.

Hepatitis B Pipeline Products Market Analysis by Molecule Types

Hepatitis B Pipeline Products Market Analysis by Molecule TypesFor more molecule type insights into the Hepatitis B pipeline products market, download a free report sample

Competitive Landscape

Some of the leading players in the Hepatitis B pipeline drugs market are Aligos Therapeutics Inc, Tekmira Pharmaceuticals Corporation, Assembly Biosciences Inc, Johnson & Johnson, Beijing Kawin Technology Share-Holding Co Ltd, Vir Biotechnology Inc, Antios Therapeutics Inc, Ascletis Pharma Inc, F. Hoffmann-La Roche Ltd, and Shanghai Zhimeng Biopharma Inc.

Aligos Therapeutics Inc: Aligos Therapeutics, Inc (Aligos), is a clinical-stage biopharmaceutical company that develops products for the treatment of viral infections and liver diseases. It develops pipeline products for the treatment of various viral infections that include chronic hepatitis B (CHB), nonalcoholic steatohepatitis (NASH), coronaviruses, and liver diseases. The company operates in the United States and Europe. Aligos is headquartered in South San Francisco, California, the United States.

Assembly Biosciences Inc: Assembly Biosciences Inc (Assembly), formerly Ventrus Biosciences Inc is a biotechnology company that develops, discovers, and commercializes small molecule therapies. The company develops therapies for the treatment of infectious diseases such as macrobiotic therapies for Clostridium difficile (C. difficile) infections (CDI) and chronic hepatitis B virus (HBV). It also develops Gemicel platform technology that helps targeted oral delivery vaccines, small molecules, live biotherapeutics, and complex macromolecules that are aimed at specific regions in the gastrointestinal tract (GI). Assembly’s HBV Cure program targets chronic hepatitis B virus infection. The company owns and operates its research and development facilities located in Indiana, New York, and California, the US. Assembly is headquartered in South San Francisco, the US.

Hepatitis B Pipeline Products Market Analysis by Players

Hepatitis B Pipeline Products Market Analysis by Players

To know more about the leading players in the Hepatitis B pipeline products market, download a free report sample

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatitis B (Infectious Disease).

  • The pipeline guide reviews pipeline therapeutics for Hepatitis B (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

  • The pipeline guide reviews key companies involved in Hepatitis B (Infectious Disease) therapeutics and enlists all their major and minor projects.

  • The pipeline guide evaluates Hepatitis B (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.

  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

  • The pipeline guide reviews the latest news related to pipeline therapeutics for Hepatitis B (Infectious Disease)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  • Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for Hepatitis B (Infectious Disease).

  • Classify potential new clients or partners in the target demographic.

  • Develop tactical initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding Hepatitis B (Infectious Disease) pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

Abhelix LLC
Achelois Cell Therapy
Ai-biopharma SAS
AiCuris Anti-infective Cures AG
Albireo Pharma Inc
Aligos Therapeutics Inc
AlloVir Inc
AlphaMab Co Ltd
Alphamab Oncology
Altimmune Inc
Ancora Biotech LLC
Antios Therapeutics Inc
APITBIO Co Ltd
Apros Therapeutics Inc
Arcturus Therapeutics Holdings Inc
Ascendo Biotechnology Inc
Ascentage Pharma Group International
Ascletis Pharma Inc
Assembly Biosciences Inc
AstriVax NV
Aucta Pharmaceuticals LLC
Auro Vaccines LLC
Avalia Immunotherapies Ltd
Beam Therapeutics Inc
Beijing Advaccine Biotechnology Company Ltd
Beijing Junke Huayuan Pharmaceutical Technology Co Ltd
Beijing Kawin Technology Share-Holding Co Ltd
Beijing Minhai Biotechnology Co Ltd
Benitec Biopharma Inc
Biological E Ltd
Biomics Biopharma Ltd
BioNet-Asia Co Ltd
Biotron Ltd
Bluejay Therapeutics Inc
Bolder Biotechnology Inc
Bonac Corp
Brandenburg Antiinfektiva GmbH
Bukwang Pharmaceutical Co Ltd
CaroGen Corp
Casterbridge Pharmaceuticals Inc
CHA Vaccine Institute Co Ltd
Chengdu Hyperway Pharmaceutical Co Ltd
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Chong Kun Dang Pharmaceutical Corporation
Chongqing Jiachen Biotechnology Ltd
Chongqing Zhifei Biological Products Co Ltd
Cinkate Corp
ClearB Therapeutics Inc
CN Bio Innovations Ltd
Cocrystal Pharma Inc
Collaborations Pharmaceuticals Inc
ConserV Bioscience Ltd
Curigin Co Ltd
CyTuVax BV
DelSiTech Ltd
Dicerna Pharmaceuticals Inc
Dong-A ST Co Ltd
Door Pharmaceuticals LLC
Drug Farm Inc
Emergex Vaccines Holding Ltd
Enanta Pharmaceuticals Inc
Enochian Biosciences Inc
Enyo Pharma SA
Escient Pharmaceuticals Inc
Etna Biotech Srl
Evotec SE
Evrys Bio
Exavir Therapeutics Inc
Excision BioTherapeutics Inc
F. Hoffmann-La Roche Ltd
FortuneRock (China) Ltd
Fresh Tracks Therapeutics Inc
Fujian Cosunter Pharmaceutical Co Ltd
GemVax & KAEL Co Ltd
GeneCure Biotechnologies LLC
GeneLancet Biosciences Inc
GeneScience Pharmaceuticals Co Ltd
GeoVax Labs Inc
Gilead Sciences Inc
Ginkgo Tree Pharmaceutical (Suzhou) Co Ltd
Globeimmune Inc
GNI Group Ltd
Golden Biotechnology Corp
Grifols SA
GSK plc
Guangdong East Sunshine Pharmaceutical Co Ltd
Guangxi Hebabiz Pharmaceutical Co Ltd
Guangzhou Henovcom Bioscience Co Ltd
Guangzhou Lupeng Pharmaceutical Co Ltd
Guangzhou Yipinhong Pharmaceutical Co Ltd
Hangzhou Metai Pharmaceutical Technology Co Ltd
HEC Pharma Co Ltd
Henan Genuine Biotech Co Ltd
Hepagene Therapeutics Shanghai Inc
Hepion Pharmaceuticals Inc
Huahui Anjian (Beijing) Biotechnology Co Ltd
ImmuneMed Inc
Immunocore Limited
Indaptus Therapeutics Inc
Inovio Pharmaceuticals Inc
Ionis Pharmaceuticals Inc
IRBM Science Park SpA
ISA Pharmaceuticals BV
ISR Immune System Regulation Holding AB
Jeil Pharmaceutical Co Ltd
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Johnson & Johnson
Jubilant Therapeutics Inc
Kainos Medicine Inc
Kyung Dong Co Ltd
LG Chem Ltd
Ligand Pharmaceuticals Inc
Lion TCR Pte Ltd
Max Biopharma Inc
Maxwell Biosciences Inc
Microbiotix Inc
Nanjing Yuandasai Weixin Biomedical Co Ltd
Novo Medi Sciences Pvt Ltd
Nucorion Pharmaceuticals Inc
OliX Pharmaceuticals Inc
Oncolys BioPharma Inc
Palisades Therapeutics
Palo Alto pharmaceuticals Inc
PeLeMed Co Ltd
PharmaEssentia Corp
Prazer Therapeutics
Precigen Inc
Precision Biosciences Inc
Profarma
Prosit Sole Biotechnology (Beijing) Co Ltd
Protheragen Inc
Qilu Pharmaceutical Co Ltd
Regeneron Pharmaceuticals Inc
Regulus Therapeutics Inc
Replicor Inc
Resonance Health Ltd
REYON Pharmaceutical Co Ltd
Rodos BioTarget GmbH
Samjin Pharm Co Ltd
SCG Cell Therapy Pte Ltd
Sclnow Biotechnology Co Ltd
SFA Therapeutics Inc
Shanghai Ark Biopharmaceutical Co Ltd
Shanghai Changsen Pharmaceutical Co Ltd
Shanghai Henlius Biotech Inc
Shanghai HEP Pharmaceutical Co Ltd
Shanghai Jinwei Biotechnology Co Ltd
Shanghai Zhimeng Biopharma Inc
Shantha Biotechnics Pvt Ltd
Shenzhen BinDeBio Ltd
Shionogi & Co Ltd
Sichuan Kelun Pharmaceutical Co Ltd
Silverback Therapeutics Inc
Sinovac Biotech Ltd
Sirnaomics Ltd
SL VaxiGen Inc
SQZ Biotechnologies Co
Staidson BioPharma Inc
Statera Biopharma Inc
Suzhou Ribo Life Sciences Co Ltd
Suzhou Zelgen Biopharmaceutical Co Ltd
Svenska Vaccinfabriken Produktion AB
Taiga Biotechnologies Inc
TaiGen Biotechnology Co Ltd
Takeda Pharmaceutical Co Ltd
Tekmira Pharmaceuticals Corporation
Tetranov International Inc
Tevogen Bio Inc
Theravectys SA
ToolGen Inc
Transgene SA
UBI Pharma Inc
Vaccitech Plc
Vaxart Inc
Vaxine Pty Ltd
VBI Vaccines Inc
Vir Biotechnology Inc
Viravaxx AG
Viriom Inc
Virion Therapeutics LLC
Virocovax
ViroStatics SRL
VLP Biotech Inc
Xi'an Xintong Pharmaceutical Research Co Ltd
Xi'An Yufan Biotechnology Co Ltd
Yangshengtang Co Ltd
Yisheng Biopharma Co Ltd
Zelluna Immunotherapy AS
Zhengda Tianqing Pharmaceutical Group Co Ltd
Zhuhai Trinomab Biotechnology Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Hepatitis B – Overview

Hepatitis B – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Hepatitis B – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hepatitis B – Companies Involved in Therapeutics Development

Hepatitis B – Drug Profiles

Hepatitis B – Dormant Projects

Hepatitis B – Discontinued Products

Hepatitis B – Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Hepatitis B, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Products under Development by Universities/Institutes, 2022 (Contd..1)

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Hepatitis B – Dormant Projects, 2022

Hepatitis B – Discontinued Products, 2022

Hepatitis B – Discontinued Products, 2022 (Contd..1)

Hepatitis B – Discontinued Products, 2022 (Contd..2)

Figures

List of Figures

Number of Products under Development for Hepatitis B, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently asked questions

  • What are the key targets in the Hepatitis B pipeline products market?

    The key targets in the Hepatitis B pipeline products market are Hepatitis B Virus Surface Antigen, Capsid Protein, Interferon Alpha/Beta Receptor 1, Interferon Alpha/Beta Receptor 2, Reverse Transcriptase, Sodium/Bile Acid Cotransporter, Hepatitis B Virus Core Antigen, Hepatitis B Virus DNA Polymerase, Programmed Cell Death 1 Ligand 1, Toll Like Receptor 7, and others.

  • What are the key mechanisms of action in the Hepatitis B pipeline products market?

    The key mechanisms of action in the Hepatitis B pipeline products market are Hepatitis B Virus Surface Antigen Inhibitor, Capsid Protein Inhibitor, Interferon Alpha/Beta Receptor 1 Agonist, Interferon Alpha/Beta Receptor 2 Agonist, Reverse Transcriptase Inhibitor, Sodium/Bile Acid Cotransporter Inhibitor, Programmed Cell Death 1 Ligand 1 Inhibitor, Toll Like Receptor 7 Agonist, Toll Like Receptor 8 Agonist, DNA Polymerase Inhibitor, and others.

  • What are the key routes of administration in the Hepatitis B pipeline products market?

    The key routes of administration in the Hepatitis B pipeline products market are oral, subcutaneous, intramuscular, intravenous, parenteral, intradermal, inhalational, intralesional, intrathecal, intrauterine, and others.

  • What are the key molecule types in the Hepatitis B pipeline products market?

    The key molecule types in the Hepatitis B pipeline products market are small molecule, subunit vaccine, antisense RNAi Oligonucleotide, monoclonal antibody, recombinant vector vaccine, vaccine, gene therapy, DNA vaccine, recombinant protein, cell therapy, and others.

  • Who are the leading players in the Hepatitis B pipeline products market?

    Some of the leading players in the Hepatitis B pipeline products market are Aligos Therapeutics Inc, Tekmira Pharmaceuticals Corporation, Assembly Biosciences Inc, Johnson & Johnson, Beijing Kawin Technology Share-Holding Co Ltd, Vir Biotechnology Inc, Antios Therapeutics Inc, Ascletis Pharma Inc, F. Hoffmann-La Roche Ltd, and Shanghai Zhimeng Biopharma Inc.

Hepatitis B Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update standard reports
Currency USD
$2,500

Can be used by individual purchaser only

Most Popular
$5,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$7,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Hepatitis B Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Infectious Disease reports
Pharmaceuticals
New
Antibody-Drug Conjugates (ADC) Overview, Industry Trends, Marketed and Pipeline Products,…
$6,995 | March 2024
Pharmaceuticals
New
Cell and Gene Therapies in Ophthalmology - Disease Overview, Treatment…
$6,995 | March 2024
Pharmaceuticals
New
Generic Drugs - Physician Perspective - Thematic Intelligence
$1,495 | March 2024
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Hepatitis B Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Hepatitis B Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more